Original Publication Date: 1 February, 2015
Publication / Source: Future Oncology
Authors: Lindsay C Stansfield, Wilson I Gonsalves & Francis K Buadi
Novel drugs such as immunomodulators and proteasome inhibitors have improved the survival of patients with multiple myeloma. Like all therapeutic agents, appropriate dosing based on metabolism and clearance is important to maintain efficacy while avoiding toxicity. Hepatic impairment (HI) in multiple myeloma patients is rare but well described either due to disease or therapy-related factors.